Gilead Sciences
GILD
1,768 hedge funds and large institutions have $89B invested in Gilead Sciences in 2022 Q4 according to their latest regulatory filings, with 290 funds opening new positions, 560 increasing their positions, 737 reducing their positions, and 95 closing their positions.
205% more first-time investments, than exits
New positions opened: 290 | Existing positions closed: 95
49% more funds holding in top 10
Funds holding in top 10: 43 → 64 (+21)
43% more capital invested
Capital invested by funds: $62.1B → $89B (+$26.9B)
10% more funds holding
Funds holding: 1,603 → 1,768 (+165)
1.69% more ownership
Funds ownership: 80.46% → 82.15% (+1.7%)
3% less call options, than puts
Call options by funds: $1.24B | Put options by funds: $1.27B
24% less repeat investments, than reductions
Existing positions increased: 560 | Existing positions reduced: 737
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.07B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$881M |
| 3 |
Barclays
London,
United Kingdom
|
+$328M |
| 4 |
BlackRock
New York
|
+$245M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$214M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$303M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$176M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$147M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$138M |
| 5 |
VanEck Associates
New York
|
-$133M |
GILD Hedge Fund Activity: Q4 2022 in Review
1,768 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q4 2022, worth a combined $89B — up 43% from $62.1B a quarter earlier.
Buyers outnumbered sellers: 290 funds opened new GILD positions and 95 closed out — a net gain of 195 holders — while 560 added to existing stakes and 737 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.07B. The largest seller was Arrowstreet Capital, cutting an estimated $303M.
- 1,768 institutional investors held Gilead Sciences (GILD) as of Q4 2022, up from 1,603 in Q3 2022.
- Funds reported $89B of Gilead Sciences stock for Q4 2022, up 43% quarter-over-quarter.
- 290 funds opened new Gilead Sciences positions in Q4 2022 and 95 closed out, a net change of +195 holders.
- The largest Gilead Sciences buyer in Q4 2022 was Fidelity Investments, an estimated $1.07B added.
- The largest Gilead Sciences seller in Q4 2022 was Arrowstreet Capital, an estimated $303M sold.
Based on aggregated 13F filings for Q4 2022.